NEW YORK, Feb 21 – Variagenics said Wednesday it sold its NuCleave genotyping and haplotyping system to the Amsterdam Genomics Center at the University of Amsterdam.
The Amsterdam Genomics Center is Variagenics’ second announced customer for NuCleave. Variagenics launched NuCleave in the fourth quarter of 2000 and placed its first system at Covance, which is using the system for genetic variance determination in clinical trials.
Frank Baas of the center will use the system in population studies looking at genetic-based susceptibility and pharmacogenomics. Baas runs the Amsterdam Medical Center’s sequence and detection facility and performs diagnostic DNA tests for peripheral neuropathy at the Amsterdam Genomics Center, which was founded recently to increase attention to the study of genomics at the university. The parties did not disclose the financial terms of the agreement.
"In our analysis of available technologies, we identified the NuCleave system as the most suitable, in terms of performance and value, to our research and clinical programs," Baas said in a statement. "We have collaborated with Variagenics before and are eager to apply their technology to our efforts in analyzing genetic variation and in diagnosing inherited disease."
NuCleave, which Variagenics jointly developed with Waters, combines DNA sample purification technology made by Waters with chemical cleavage genotyping and haplotyping technologies. The technology enables automated detection of SNPs and other genetic variances, through use of mass spectrometry and robotic instruments.
The technology is designed for the needs of the clinical lab for accurate genotyping of patient samples, rather than the high-throughput needs of a research lab analyzing large numbers of genetic variances, Variagenics said.